# A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

> **NCT02871570** · PHASE1 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 16 (actual)

## Conditions studied

- Moderate Hepatic Impairment
- Normal Hepatic Function

## Interventions

- **DRUG:** Rivipansel

## Key facts

- **NCT ID:** NCT02871570
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-02
- **Final completion:** 2017-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02871570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02871570, "A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02871570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*